Title:A New Scoring System to Differentiate Bladder Cancer from Intravesical
Prostatic Protrusion in the Bladder Neck: BCa-IPP Score
Volume: 20
Author(s): Ali Kaan Yildiz*, Cagri Oktem, Bugra Bilge Keseroglu, Turgay Kacan, Berat Cem Ozgur, Omer Gokhan Doluoglu and Tolga Karakan
Affiliation:
- Department of Urology, Ankara City Hospital, Ankara, Turkey
Keywords:
Benign, Bladder, Cancer, Hematuria, Prostate, Ultrasound.
Abstract:
Objective:
The aim of this study was to explore the criteria that can predict bladder cancer among the lesions that could not be differentiated from intravesical
prostate protrusion (IPP) and to create a scoring system using these criteria.
Methods:
A retrospective analysis was made of patients with an ultrasound report indicating lesions in the bladder neck, for which differentiation between
bladder cancer and IPP could not be determined. A total of 174 patients diagnosed with bladder cancer (n=102) or benign prostate lesion (n=72)
according to the biopsy results were enrolled in the study. Hemoglobin, prostate-specific antigen (PSA), prostate volume (PV), bladder wall
thickness (BWT), lesion height (LH), and the ratio of lesion width to base (LW/B) were compared between the two groups.
Results:
ROC analysis revealed an AUC value >0.7 for all factors, and the best cut-off value was identified for each factor. In the multivariate analysis, by
determining a score for each factor according to the ORs, the BCa-IPP scoring system was developed to provide a total score in the range of
minimum 0 and maximum 15. In the ROC analysis, the AUC value was 0.954 (95% CI: 0.923–0.986) for the BCa-IPP score. The best cut-off
value was found to be 10, with sensitivity of 0.93 and specificity of 0.85.
Conclusion:
Using simple laboratory and ultrasound findings, the BCa-IPP scoring system was created, which was seen to have high predictive value and can
be easily applied in the clinic. The BCa-IPP scoring system is a non-invasive test that can be successfully applied for the differentiation of bladder
cancer from benign lesions.
